Financial News

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

(Bloomberg) -- Eli Lilly & Co. is on a record spending spree, announcing acquisitions worth more than $20 billion so far in 2026 as the drugmaker expands beyond its blockbuster obesity franchise. Most Read from BloombergIran’s Khamenei Says No Going Back for Middle East Rocked by WarSingapore Hands Byju's Founder His First Ever Jail TermPutin Signs Law on Use of Army to Aid Russians Detained AbroadRussia Tells US to Evacuate Its Diplomats and Citizens From KyivUS Strikes Targets in Iran Even as

By Rishika Sadam and Sai Ishwarbharath B HYDERABAD/BENGALURU, May 27 (Reuters) - U.S. carrier American Airlines Group plans to double headcount at its India technology hub to about 800 by early next

As Lilly completes its pivotal program for its “triple-G” drug, Phase 1 data from Kailera partner Hengrui suggest their drug might spur greater weight loss.

Semiconductor powerhouse Micron Technology Inc. (NASDAQ:MU) vaulted on Tuesday, officially crossing the $1 trillion market capitalization milestone following a rally driven by demand for artificial intelligence (AI). Historic Market Cap Milestone The shares of the Idaho-based chipmaker closed 19.29% higher at $895.88, locking in a final market value of $1.010 trillion. According to data from CompaniesMarketCap, this monumental surge enabled Micron Technology to comfortably overtake legacy giants

BofA cut its HIMS price target to $25 from $28, while warning that the company’s 2026 outlook depends on a “significant” ramp-up in GLP-1 growth.

Eli Lilly acquired three infectious diseases companies for up to $3.83 billion. Lilly stock ticked lower in response.

(Bloomberg) -- Wall Street kicked off the holiday-shortened week with stocks joining bonds higher as hopes for a peace deal between the US and Iran overshadowed military strikes in the Persian Gulf.Most Read from BloombergIran’s Khamenei Says No Going Back for Middle East Rocked by WarRussia Tells US to Evacuate Its Diplomats and Citizens From KyivUS Strikes Targets in Iran Even as Trump Hails Progress on DealPutin Signs Law on Use of Army to Aid Russians Detained AbroadThese AI Gurus Are Chargi

Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index shedding 0.7% an

Micron (MU) is having its best trading day since 2011, on track to close at a valuation of $1 trillion, which would make its market cap nearly tied with those of Eli Lilly (LLY) and Berkshire Hathaway (BRK-B, BRK-A). Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at Micron's market action in the video above.

Micron (MU) is having its best trading day since 2011, on track to close at a valuation of $1 trillion, which would make its market cap nearly tied with those of Eli Lilly (LLY) and Berkshire Hathaway (BRK-B, BRK-A). Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at Micron's market action in the video above.

Eli Lilly agreed to buy three vaccine developers targeting shingles, bacterial infections and Epstein-Barr Virus.

Eli Lilly agreed to buy three vaccine developers targeting shingles, bacterial infections and Epstein-Barr Virus.

Why Analysts See Eli Lilly as a Long-Term Winner in the Weight-Loss Race

Why Analysts See Eli Lilly as a Long-Term Winner in the Weight-Loss Race

Healthcare stocks were lower Tuesday afternoon, with the NYSE Healthcare Index shedding 0.6% and the

Healthcare stocks were lower Tuesday afternoon, with the NYSE Healthcare Index shedding 0.6% and the

Weight-loss drugs such as Novo Nordisk's Ozempic and Wegovy are disrupting eating habits, and restaurants should prepare for changes, an analyst says. More than half of Americans taking GLP-1 drugs including Eli Lilly's Mounjaro have changed their eating habits, a survey by UBS found. "Our survey results suggest GLP-1 users are more likely to eat less calories while taking GLP-1 drugs, with survey respondents dining out less, changing eating habits, and appreciating healthier foods more," UBS analysts led by Dennis Geiger said in a note to clients.

Weight-loss drugs such as Novo Nordisk's Ozempic and Wegovy are disrupting eating habits, and restaurants should prepare for changes, an analyst says. More than half of Americans taking GLP-1 drugs including Eli Lilly's Mounjaro have changed their eating habits, a survey by UBS found. "Our survey results suggest GLP-1 users are more likely to eat less calories while taking GLP-1 drugs, with survey respondents dining out less, changing eating habits, and appreciating healthier foods more," UBS analysts led by Dennis Geiger said in a note to clients.

Walmart (NasdaqGS:WMT) is set to enter the top 10 of the Russell 3000 Index during the June 2026 reconstitution, replacing Eli Lilly. The index change follows Q1 results where Walmart reported record sales alongside a cautious earnings outlook that triggered a sharp stock pullback. Two senior executives are leaving the company as Walmart reshapes its leadership team and refines its long term priorities. For you as an investor, Walmart sits at the crossroads of big box retail, grocery, and e...

Walmart (NasdaqGS:WMT) is set to enter the top 10 of the Russell 3000 Index during the June 2026 reconstitution, replacing Eli Lilly. The index change follows Q1 results where Walmart reported record sales alongside a cautious earnings outlook that triggered a sharp stock pullback. Two senior executives are leaving the company as Walmart reshapes its leadership team and refines its long term priorities. For you as an investor, Walmart sits at the crossroads of big box retail, grocery, and e...

Eli Lilly (NYSE:LLY) announced a US$3.8b series of acquisitions in vaccines, including Curevo, LimmaTech Biologics, and Vaccine Company. The company is expanding its presence in infectious disease prevention alongside its established obesity and diabetes drug portfolio. Phase 3 trial results for Eli Lilly’s obesity drug candidate retatrutide showed record weight loss outcomes and strong efficacy signals. These developments introduce fresh data points for investors tracking Eli Lilly’s R&D...

(Bloomberg) -- Eli Lilly & Co. is on a record spending spree, announcing acquisitions worth more than $20 billion so far in 2026 as the drugmaker expands beyond its blockbuster obesity franchise. Most Read from BloombergIran’s Khamenei Says No Going Back for Middle East Rocked by WarUS Strikes Targets in Iran Even as Trump Hails Progress on DealRussia Tells US to Evacuate Its Diplomats and Citizens From KyivPutin Signs Law on Use of Army to Aid Russians Detained AbroadThese AI Gurus Are Charging

Positive Phase 1b results support plans for a Phase 2 trial later this year.

The drugmaker is buying three vaccine developers to strengthen its infectious disease pipeline.

Eli Lilly and Co (NYSE:LLY) has announced agreements to acquire three vaccine developers, Curevo, LimmaTech Biologics AG, and Vaccine Company, in transactions valued at up to $3.83 billion combined, as the company expands its research and development efforts into infectious disease...

"Micron's great," Trump said as the chipmaker topped $1 trillion. Prediction markets are now betting on whether Washington takes a stake next.(

The Nasdaq Composite and S&P 500 were up, while the Dow Jones Industrial Average was down slightly t

In a challenge brought by Eli Lilly and Company, BBB National Programs’ National Advertising Division recommended that Noom, Inc. modify or discontinue its Microdose GLP-1RX Program “A Smaller Dose. A SmarterStart” claim.New York, NY, May 26, 2026 (GLOBE NEWSWIRE) -- In a challenge brought by Eli Lilly and Company, BBB National Programs’ National Advertising Division recommended that Noom, Inc. modify or discontinue its Microdose GLP-1RX Program “A Smaller Dose. A SmarterStart” claim. Lilly and

Novo Nordisk's EU label expansions may widen semaglutide use and boost volumes, but pricing pressure and Lilly rivalry can limit recovery.